Advances in diagnosis and treatment of perimenopausal syndrome
Author:
Chen Wanying1, Chen Mengjuan2, Tang Huimin1, Wei Weiwei1, Shao Panqiu1, Dou Shulan1, Wu Jia1, Lu Bingying1, Shi Ruxia1, Chen Jiming1
Affiliation:
1. Department of Gynecology, The Affiliated Changzhou No. 2 People’s Hospital of Nanjing Medical University , Changzhou , Jiangsu, 213003 , PR China 2. Zhoukou Maternal and Child Health Hospital , Zhoukou , Henan, 466000 , PR China
Abstract
Abstract
With the development and progress of society, people’s average life expectancy has increased, and relevant literature reports that the number of postmenopausal women in China continues to increase. With lifespans extended, the transition period and post-menopause period have become the longest essential period in every woman’s life. The life quality of women troubled by perimenopausal syndrome has been significantly reduced, which also places a burden on families and society. It is well known that hormone replacement therapy plays a vital role in improving women’s menopause-related symptoms and is the most effective medical measure. With research ongoing into the treatment of menopausal symptoms in different patients, dose size, treatment duration, and medication regimens for hormones are still hot topics of discussion. This article reviews the definition, clinical diagnosis, staging, clinical manifestations, and treatment of menopause and explores the current diagnosis and treatment scenarios of perimenopausal syndrome.
Publisher
Walter de Gruyter GmbH
Subject
General Agricultural and Biological Sciences,General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Neuroscience
Reference21 articles.
1. Chen R, Yu Q, Xu K-h, Xie M-q, Lei X-m, Ren M-l, et al. Survey on characteristics of menopause of Chinese women with the age of 40-60 years at gynecological clinic from 14 hospitals. Zhonghua Fu Chan Ke Za Zhi. 2013;48(10):723–7. 2. Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, et al. Executive summary of the stages of reproductive aging workshop + 10: Addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab. 2012;97(4):1159–68. 3. Seltzer VL, Benjamin F, Deutsch S. Perimenopausal bleeding patterns and pathologic findings. J Am Med Women Assoc. 19721990;45(4):132–4. 4. Hodis HN, Mack WJ, Henderson VW, Shoupe D, Budoff MJ, Hwang-Levine J, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374(13):1221–31. 5. Gordon JL, Rubinow DR, Eisenlohr-Moul TA, Xia K, Schmidt PJ, Girdler SS. Efficacy of transdermal estradiol and micronized progesterone in the prevention of depressive symptoms in the menopause transition: A randomized clinical trial. JAMA Psychiatry. 2018;75(2):149–57.
|
|